--- title: "Teva prevails in first U.S. jury trial over Paragard IUD injury claims" description: "Teva Pharmaceuticals won its first jury trial regarding claims related to its Paragard IUD, with the jury rejecting a plaintiff's allegations of inadequate warnings about the device's potential to bre" type: "news" locale: "en" url: "https://longbridge.com/en/news/274862165.md" published_at: "2026-02-04T20:10:55.000Z" --- # Teva prevails in first U.S. jury trial over Paragard IUD injury claims > Teva Pharmaceuticals won its first jury trial regarding claims related to its Paragard IUD, with the jury rejecting a plaintiff's allegations of inadequate warnings about the device's potential to break during removal. This trial is part of over 3,800 lawsuits against Teva, which sold Paragard to CooperSurgical in 2017. The verdict supports Teva's defense, asserting that the company adequately informed physicians about the risks. This case is the first of three bellwether trials in the ongoing litigation. Teva faces over 3,800 lawsuits over Paragard IUD claims Trial was the first bellwether to test the claims Teva sold Paragard to CooperSurgical in 2017 By Diana Novak Jones Feb 4 (Reuters) - A jury in Atlanta federal court has sided with Teva Pharmaceuticals in the first trial testing claims the company failed to warn women that its Paragard intrauterine contraceptive device could break apart during removal. After a two-week trial, the jury on Tuesday rejected plaintiff Pauline Rickard’s attempt to hold the company liable for allegedly failing to warn her about problems with its product. Rickard’s case, which is among more than 3,800 lawsuits over similar claims, was the first so-called “bellwether” in the litigation — trials that are used to test claims before juries and determine their value for potential settlements. Erin Copeland, an attorney for Rickard, said the verdict doesn’t change what the women who have sued over Paragard have experienced. “We will continue to expose what has been buried in the company documents, including the conduct that kept women in the dark, and demand accountability, regardless of the outcome of any one trial,” Copeland said. In a statement, a spokesperson for Teva said the verdict affirms its position in the case and “we will continue to vigorously defend against claims that we believe misrepresent this important product’s safety profile.” Paragard is a non-hormonal contraceptive device, or IUD made from copper that can be implanted in the uterus and used for years. The lawsuits claim the company failed to warn women that the IUD can break apart while inside the body, causing injuries that can impact fertility and often requiring surgical removal. Rickard sued the company in 2021, claiming she needed multiple procedures to remove her Paragard IUD. Her case was among the thousands that have been centralized before a single judge in the Atlanta federal court in a multi-district litigation. Teva sold Paragard to CooperSurgical in 2017. Rickard’s claims against CooperSurgical were dismissed separately. Teva faces claims from people like Rickard, who received their IUDs when the company owned the Paragard product. Teva has argued that the plaintiffs’ claims are preempted by federal law governing drug labeling and said the company adequately warned physicians of the risk of breakage. Rickard’s case is the first of three planned bellwether trials coming up in the next few months. The case is In Re: Paragard IUD Products Liability Litigation, U.S. District Court for the Northern District of Georgia, No 1:20-md-02974. For the plaintiffs: Erin Copeland of Fibich Leebron Copeland & Briggs; and Nicole Berg of Keller Postman For Teva: Jaime Santos of Goodwin Procter; and Christopher Morris and Pamela Ferrell of Butler Snow ### Related Stocks - [TEVA.US - Teva Pharmaceutical Industries](https://longbridge.com/en/quote/TEVA.US.md) - [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md) - [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 礼来升级 Zepbound 巩固优势、一支用整月！诺和诺德新药临床失利股价暴跌 | 礼来周一推出 Zepbound 多剂量 KwikPen 注射装置，患者仅需一支笔即可完成一个月四次给药，最低月价 299 美元，并已获 FDA 批准扩展标签。受此消息提振，礼来股价盘中涨超 5%。与此同时，竞争对手诺和诺德的下一代减肥药 C | [Link](https://longbridge.com/en/news/276630276.md) | | 梯瓦制药｜10-K：2025 财年营收 173 亿美元超过预期 | | [Link](https://longbridge.com/en/news/274669800.md) | | 15:22 ET 两种男性避孕方案进入 II 期临床试验 | NEXT Life Sciences 已将两种男性避孕选择，Plan A™ 和 NLS-133，推进至第二阶段临床试验。Plan A™ 是一种长效、非激素、可按需可逆的避孕方法，而 NLS-133 是一种提供 24 小时保护的非激素药丸。这 | [Link](https://longbridge.com/en/news/276374321.md) | | 梯瓦制药｜8-K：2025 财年营收 173 亿美元超过预期 | | [Link](https://longbridge.com/en/news/273988886.md) | | 美国食品药品监督管理局（FDA）已接受梯瓦制药的新型长效精神分裂症治疗药物的申请 | 梯瓦制药宣布，FDA 已接受其新药申请，针对 TEV-749，这是一种长效精神分裂症治疗药物。该注射药物旨在提高治疗依从性，并在第三阶段 SOLARIS 试验中显示出良好的结果。尽管过去一年股价上涨了 12.4%，但当前交易显示出混合的动能 | [Link](https://longbridge.com/en/news/276609439.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.